Tiagabine

Sort by

Tiagabine -D5. HCl

  • CAT Number DCTI-A-190
  • CAS Number 109857-73-0
  • Molecular Formula C20H21D5ClNO2S2
  • Molecular Weight 417.03

Tiagabine diol analog

  • CAT Number DCTI-C-1246
  • CAS Number 2125725-84-8
  • Molecular Formula C20H27NO4S2
  • Molecular Weight 409.56

TIAGABINE HYDROCHLORIDE STAGE – I IMP

  • CAT NUMBER DCTI-C-2741
  • CAS NUMBER 938159-01-4
  • MOLECULAR FORMULA C21H27NO2S2 (Free base); C21H28ClNO2S2 (HCl Salt)
  • MOLECULAR WEIGHT 389.57 (Free base); 426.03 (HCl Salt)

Tiagabine keto analog

  • CAT Number DCTI-C-1247
  • CAS Number 161014-55-7
  • Molecular Formula C20H25NO3S2
  • Molecular Weight 391.54

General Information

Tiagabine Impurities and Tiagabine

Daicel Pharma is a trusted provider known for synthesizing premium-grade Tiagabine impurity standards, including, Tiagabine diol analog, Tiagabine hydrochloride stage – I imp, and Tiagabine keto analog. These impurities play a crucial role in precisely analyzing the active pharmaceutical ingredient Tiagabine, ensuring its quality, stability, and biological safety. Moreover, Daicel Pharma offers a customized synthesis of Tiagabine impurities, catering to customers’ specific requirements worldwide.

Tiagabine [CAS: 115103-54-3] is an anticonvulsant primarily used as an adjunctive treatment for partial seizures in adult and pediatric patients. It combines with other antiepileptic medications to help control and manage panic attacks.

Tiagabine: Use and Commercial Availability   

Tiagabine acts as an anticonvulsant for adjunctive treatment in partial seizures and, in some cases, epilepsy. The drug is associated with its capacity to enhance the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system.

Tiagabine is available under Gabitril, which contains the active ingredient, Tiagabine.

Tiagabine Structure and Mechanism of Action Tiagabine Structure and Mechanism of Action

The chemical name of Tiagabine is (3R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid. Its chemical formula is C20H25NO2S2, and its molecular weight is approximately 375.6 g/mol.

Tiagabine inhibits the reuptake of GABA into presynaptic nerve terminals, enhancing GABA-ergic transmission.

Tiagabine Impurities and Synthesis

During Tiagabine preparation1, impurity formation is possible, compromising its effectiveness. They can arise from various sources, including the raw materials, intermediates, and chemicals utilized to synthesize Tiagabine. Close management and monitoring of impurities ensure the drug’s efficacy and safety.

Daicel offers a wholesome and integrated Certificate of Analysis (CoA) for Tiagabine impurity standards, such as Tiagabine diol analog, Tiagabine hydrochloride stage – I imp, and Tiagabine keto analog. The Certificate of Analysis (CoA) furnishes comprehensive characterization data, encompassing 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Furthermore, we give a detailed 13C-DEPT analysis of product delivery. Leveraging advanced technology and expertise, Daicel Pharma can synthesize any unknown Tiagabine impurity or degradation product. We also offer labeled compounds to facilitate the quantification of generic Tiagabine efficacy. In bioanalytical research and BA/BE studies, we provide a deuterium-labeled Tiagabine standard, Tiagabine-D5 HCl.

References
FAQ's

Frequently Asked Questions

Impurities in Tiagabine can affect the drug's purity, potency, and safety. They can also affect the drug's efficacy and cause unwanted side effects.

Analytical testing is vital for detecting impurities in Tiagabine as it yields accurate and reliable information about the presence and concentration of these substances.

Tiagabine impurities are quantified by comparing the impurity peaks with appropriate reference standards or calibration curves to determine their concentrations accurately using the RP-HPLC method.

Tiagabine impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart